David Buck
Stock Analyst at B. Riley Securities
(0.28)
# 4,044
Out of 4,714 analysts
14
Total ratings
21.43%
Success rate
-27.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Buck
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNOV MediciNova | Assumes: Buy | $22 | $2.13 | +932.86% | 2 | Mar 25, 2019 | |
| SUPN Supernus Pharmaceuticals | Maintains: Buy | $68 → $65 | $36.92 | +76.06% | 3 | Nov 12, 2018 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $219 → $190 | $120.56 | +57.60% | 4 | Nov 8, 2018 | |
| AMRX Amneal Pharmaceuticals | Maintains: Buy | $26 → $28 | $7.82 | +258.06% | 2 | Aug 22, 2018 | |
| ALKS Alkermes | Initiates: Buy | $60 | $29.04 | +106.61% | 1 | Jun 6, 2018 | |
| EVOK Evoke Pharma | Reinstates: Buy | $1,440 | $4.64 | +30,934.48% | 2 | Oct 19, 2017 |
MediciNova
Mar 25, 2019
Assumes: Buy
Price Target: $22
Current: $2.13
Upside: +932.86%
Supernus Pharmaceuticals
Nov 12, 2018
Maintains: Buy
Price Target: $68 → $65
Current: $36.92
Upside: +76.06%
Jazz Pharmaceuticals
Nov 8, 2018
Maintains: Buy
Price Target: $219 → $190
Current: $120.56
Upside: +57.60%
Amneal Pharmaceuticals
Aug 22, 2018
Maintains: Buy
Price Target: $26 → $28
Current: $7.82
Upside: +258.06%
Alkermes
Jun 6, 2018
Initiates: Buy
Price Target: $60
Current: $29.04
Upside: +106.61%
Evoke Pharma
Oct 19, 2017
Reinstates: Buy
Price Target: $1,440
Current: $4.64
Upside: +30,934.48%